A5023933249- Acute Myeloid Leukemia Research
- Cancer Genomics and Diagnostics
- Chronic Lymphocytic Leukemia Research
- Protein Degradation and Inhibitors
- Epigenetics and DNA Methylation
- Palliative Care and End-of-Life Issues
- Organ Transplantation Techniques and Outcomes
- Cancer-related Molecular Pathways
- Chronic Myeloid Leukemia Treatments
- Chromatin Remodeling and Cancer
- Hedgehog Signaling Pathway Studies
- Colorectal Cancer Treatments and Studies
- Genomics and Rare Diseases
- Cancer Cells and Metastasis
- Histone Deacetylase Inhibitors Research
- Genomic variations and chromosomal abnormalities
- Gastric Cancer Management and Outcomes
- 3D Printing in Biomedical Research
- BRCA gene mutations in cancer
- Organ Donation and Transplantation
- Cancer, Stress, Anesthesia, and Immune Response
- Cancer Immunotherapy and Biomarkers
University of Wisconsin–Madison
2024
Novel (United States)
2019-2022
Mayo Clinic
2019-2022
Mayo Clinic in Florida
2019-2021
Mayo Clinic in Arizona
2019
Abstract Proliferative chronic myelomonocytic leukemia (pCMML), an aggressive CMML subtype, is associated with dismal outcomes. RAS pathway mutations, mainly NRAS G12D , define the pCMML phenotype as demonstrated by our exome sequencing, progenitor colony assays and a Vav-Cre - Nras mouse model. Further, these mutations promote transformation to acute myeloid leukemia. Using multiomics platform biochemical molecular studies we show that in are unique gene expression profile enriched mitotic...
BACKGROUNDA patient-derived organoid (PDO) platform may serve as a promising tool for translational cancer research. In this study, we evaluated PDO's ability to predict clinical response gastrointestinal (GI) cancers.METHODSWe generated PDOs from primary and metastatic lesions of patients with GI cancers, including pancreatic ductal adenocarcinoma, colorectal cholangiocarcinoma. We compared PDO the observed donor same treatments.RESULTSWe report an approximately 80% concordance rate between...
The Hedgehog-regulated transcription factors GLI1 and GLI2 play overlapping roles in development disease; however, the mechanisms underlying their interplay remain elusive. We report for first time that physically functionally interact cancer cells. were shown to co-immunoprecipitate PANC1 pancreatic cells RMS13 rhabdomyosarcoma Mapping analysis demonstrated zinc finger domains of both proteins are required heteromerization. RNAi knockdown either or inhibited expression many...
PURPOSE Somatic and germline testing are increasingly used to estimate risks for patients with cancer. Although both somatic can identify genetic variants that could change a patient's care eligible treatments, the aims of these tests their technologies fundamentally different cannot be interchangeably. This study examines timing results cancer at UW Health. METHODS Eight hundred seventy-seven participants underwent testing, which was reviewed by Precision Medicine Molecular Tumor Board...
Germline mutations in CDKN2A, encoding the tumor suppressor p16, are responsible for a large proportion of familial melanoma cases and also increase risk pancreatic cancer. We identified four families through cancer probands that were affected by both cancers. These bore germline missense variant CDKN2A (47T>G), p16-L16R mutant protein associated with high occurrence. Here, we investigated biological significance this variant. When transfected into p16-null cells, was expressed at lower...
ABSTRACT Chronic myelomonocytic leukemia (CMML) is an aggressive hematological malignancy with limited treatment options. Whole exome (WES) and targeted sequencing of several independent cohorts CMML patients, comparing dysplastic (dCMML) to proliferative (pCMML) CMML, as well paired chronic phase disease acute leukemic transformation (LT), associate acquisition oncogenic RAS pathway mutations, the most common being NRAS G12D , progression. Using patient derived progenitor colony assays a...
3101 Background: PDO is a promising translational tool that recapitulates the biology and drug response of donor cancer patient. However, an unmet need to have drug-screening data available for treatment decision making in clinic. We conducted pilot study determine whether testing results will be at critical points metastatic GI patients. Methods: Metastatic patients undergoing core-needle biopsy were eligible. Tumor cells isolated from ≤4 fresh tissues grown Matrigel-based culture....